These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 29759721)

  • 1. Efficacy of Implantable Cardioverter-Defibrillator Therapy in Patients With Nonischemic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Anantha Narayanan M; Vakil K; Reddy YN; Baskaran J; Deshmukh A; Benditt DG; Adabag S
    JACC Clin Electrophysiol; 2017 Sep; 3(9):962-970. PubMed ID: 29759721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implantable Cardioverter Defibrillators for Primary Prevention of Mortality in Patients With Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.
    Stavrakis S; Asad Z; Reynolds D
    J Cardiovasc Electrophysiol; 2017 Jun; 28(6):659-665. PubMed ID: 28316104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implantable defibrillators for the prevention of mortality in patients with nonischemic cardiomyopathy: a meta-analysis of randomized controlled trials.
    Desai AS; Fang JC; Maisel WH; Baughman KL
    JAMA; 2004 Dec; 292(23):2874-9. PubMed ID: 15598919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Implantable cardioverter defibrillators for primary prevention in patients with nonischemic cardiomyopathy: A systematic review and meta-analysis.
    Akel T; Lafferty J
    Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28129469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of implantable cardioverter-defibrillator in primary prevention of total mortality in non-ischaemic cardiomyopathy: results from a meta-analysis of prospective randomized clinical trials.
    Romero J; Díaz JC; Grushko M; Quispe R; Briceno D; Avendano R; Golive A; Pina I; Natale A; Garcia MJ; Jorde UP; Di Biase L
    Europace; 2018 Sep; 20(FI2):f211-f216. PubMed ID: 29161424
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Addition of a Defibrillator to Resynchronization Therapy Decreases Mortality in Patients With Nonischemic Cardiomyopathy.
    Doran B; Mei C; Varosy PD; Kao DP; Saxon LA; Feldman AM; DeMets D; Bristow MR
    JACC Heart Fail; 2021 Jun; 9(6):439-449. PubMed ID: 33992570
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a systematic review and meta-analysis of prospective randomized clinical trials.
    Romero J; Chaudhary R; Garg J; Lupercio F; Shah N; Gupta R; Nazir T; Bozorgnia B; Natale A; Di Biase L
    J Interv Card Electrophysiol; 2017 Sep; 49(3):263-270. PubMed ID: 28674918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcomes after prophylactic ICD and CRT-D implantation in nonischemic patients: Analysis from a nationwide database of daily remote-monitoring transmissions.
    Forleo GB; Solimene F; Pisanò EC; Zanotto G; Calvi V; Pignalberi C; Maglia G; Iacopino S; Quartieri F; Biffi M; Caravati F; Curnis A; Capucci A; Senatore G; Santamaria M; Della Bella P; Manzo M; Giacopelli D; Gargaro A; D'Onofrio A
    J Cardiovasc Electrophysiol; 2019 Sep; 30(9):1626-1635. PubMed ID: 31165517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adding the implantable cardioverter-defibrillator to cardiac resynchronization therapy is associated with improved long-term survival in ischaemic, but not in non-ischaemic cardiomyopathy.
    Witt CT; Kronborg MB; Nohr EA; Mortensen PT; Gerdes C; Jensen HK; Nielsen JC
    Europace; 2016 Mar; 18(3):413-9. PubMed ID: 26378089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary prevention implantable cardioverter defibrillator in patients with non-ischaemic cardiomyopathy: a meta-analysis of randomised controlled trials.
    Barakat AF; Saad M; Elgendy AY; Mentias A; Abuzaid A; Mahmoud AN; Elgendy IY
    BMJ Open; 2017 Jun; 7(6):e016352. PubMed ID: 28637742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [ECG score to predict ICD therapies in patients with nonischemic cardiomyopathy and primary prophylactic CRT-D].
    Grett M; Christ M; Röing Gen Nölke JP; Trappe HJ
    Herzschrittmacherther Elektrophysiol; 2017 Mar; 28(1):48-53. PubMed ID: 28204917
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prophylactic use of the implantable cardioverter-defibrillator and its effect on the long-term survival, cardiovascular and sudden cardiac death in nonischemic cardiomyopathy patients-a systematic review and meta-analysis.
    Siddiqui WJ; Aggarwal S; Rafique M; Singh S; Kutalek S; Eisen HJ
    Heart Fail Rev; 2018 Mar; 23(2):181-190. PubMed ID: 29380177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differences in mode of death between men and women receiving implantable cardioverter-defibrillators or cardiac resynchronization therapy in the MADIT trials.
    Tompkins CM; Zareba W; Greenberg H; Goldstein R; McNitt S; Polonsky B; Brown M; Kutyifa V
    Heart Rhythm; 2023 Jan; 20(1):39-45. PubMed ID: 36007729
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes of Cardiac Resynchronization Therapy With or Without Defibrillation in Patients With Nonischemic Cardiomyopathy.
    Leyva F; Zegard A; Acquaye E; Gubran C; Taylor R; Foley PWX; Umar F; Patel K; Panting J; Marshall H; Qiu T
    J Am Coll Cardiol; 2017 Sep; 70(10):1216-1227. PubMed ID: 28859784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Implantable Cardioverter Defibrillator for the Primary Prevention of Sudden Cardiac Death in Patients With Nonischemic Cardiomyopathy.
    Cavalcanti R; Aboul-Hosn N; Morales G; Abdel-Latif A
    Angiology; 2018 Apr; 69(4):297-302. PubMed ID: 28554215
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiac resynchronization therapy using pacemakers vs defibrillators in patients with nonischemic cardiomyopathy: The United States experience from 2007 to 2014.
    Saba S; McLaughlin T; He M; Althouse A; Mulukutla S; Hernandez I
    Heart Rhythm; 2019 Jul; 16(7):1065-1071. PubMed ID: 31004781
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a meta-analysis of randomized controlled trials.
    Masri A; Hammadah M; Adelstein E; Jain S; Saba S
    Cardiovasc Diagn Ther; 2017 Aug; 7(4):397-404. PubMed ID: 28890876
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardioverter-defibrillator reduces mortality risk in eligible ischemic and non-ischemic cardiomyopathy patients: Sub-analysis of the multi-center Improve SCA study.
    Singh B; Hsieh YC; Liu YB; Lin KH; Joung B; Rodriguez DA; Chasnoits AR; Huang D; Zhang S; O'Brien JE; Lexcen DR; Cerkvenik J; Van Dorn B; Ching CK
    Indian Heart J; 2023; 75(2):115-121. PubMed ID: 36736459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk of Ventricular Tachyarrhythmic Events in Patients Who Improved Beyond Guidelines for a Defibrillator in MADIT-CRT.
    Sherazi S; Shah F; Kutyifa V; McNitt S; Aktas MK; Polonsky B; Zareba W; Goldenberg I
    JACC Clin Electrophysiol; 2019 Oct; 5(10):1172-1181. PubMed ID: 31648742
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.